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Classic human polyomaviruses (JC and BK viruses) become
pathogenic when reactivating from latency. For the rare skin
disease trichodysplasia spinulosa, we show that manifestations
of the causative polyomavirus (TSPyV) occur during primary
infection of the immunosuppressed host. High TSPyV loads
in blood and cerebrospinal fluid, sometimes coinciding with ce-
rebral lesions and neuroendocrine symptoms, marked the acute
phase of trichodysplasia spinulosa, whereas initiation and mat-
uration of TSPyV seroresponses occurred in the convalescent
phase. TSPyV genomes lacked the rearrangements typical for
reactivating polyomaviruses. These findings demonstrate the
clinical importance of primary infection with this rapidly ex-
panding group of human viruses and explain the rarity of
some novel polyomavirus-associated diseases.
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Human polyomaviruses (HPyVs) are known to cause severe in-
fection and cancer, especially in immunocompromized hosts.
The polyomavirus family nowadays includes 11 novel HPyVs,
along with the classic polyomaviruses JC (JCPyV) and BK
(BKPyV) [1]. JCPyV and BKPyV latently infect the majority
of the general population, with increasing adult seroprevalences
up to 60% and 90%, respectively [2]. In immunocompromised
individuals, they can reactivate and cause severe conditions,
such as progressive multifocal leukoencephalopathy (PML), ne-
phropathy, and hemorrhagic cystitis. These reactivations are
often accompanied by specific viral genome rearrangements
in the noncoding control region (NCCR) [3, 4]. Whether con-
ditions related to novel HPyVs result from reactivation is
unknown.
For one of the novel HPyVs, a causal relationship with tricho-
dysplasia spinulosa (TS) has been established. TS is a rare, dis-
figuring skin disease of severely immunocompromised patients
characterized by papules and spines on the face, alopecia of eye-
brows and lashes, and thickening of the affected skin layers [5].
The typical lesions show abundant trichodysplasia spinulosa
polyomavirus (TSPyV) replication and gene expression in the
affected hair follicles [5].
Comparable to JCPyV and BKPyV [2, 6], TSPyV is ubiquitous,
with primary infection occurring in childhood and an adult sero-
prevalence of approximately 75%. Unlike PML and nephropathy,
the number of 35 patients with documented TS worldwide is
much lower than would be expected based on the number of
susceptible, latently infected, immunocompromised hosts. In
the Netherlands, for example, only 3 TS cases were identified
between 2010 and 2015 [5], as opposed to approximately 250
BKPyV-associated nephropathy cases within the same period
[7]. Based on this discrepancy, there is reason to question the
assumption that clinically manifest HPyV infections result from
reactivation.
By systematically analyzing specific immunological and mo-
lecular markers of TSPyV infection in 2 adult immunosup-
pressed patients, we showed that the signs and symptoms of
TS are caused by disseminated primary TSPyV infection ac-
companied by high viral loads in blood and cerebrospinal
fluid (CSF). Our findings provide a logical explanation for the
low number of TS cases regardless of the high TSPyV seropre-
valence and increase our understanding of the novel HPyVs and
their clinical manifestations.
METHODS
TSPyV-specific immunoglobulin (Ig) M, IgG, and IgG avidity
measurements were performed using published Luminex and
enzyme-linked immunosorbent assay methods [6, 8]. Quantita-
tive polymerase chain reaction (PCR) was used to detect and
quantify TSPyV DNA. Additional TSPyV PCR primer sets
were designed and used for (direct) sequencing and cloning. Pe-
ripheral blood mononuclear cells and lymphocyte subsets were
obtained by Ficoll and immunodensity centrifugation. Details
regarding the methods are provided in the Supplementary
data. Because all materials were obtained for diagnostic purpos-
es, medical ethical approval was not needed, as confirmed by
the institutional review board. Both patients consented to the
study in writing.
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RESULTS
Case Descriptions
Patient 1, a 54-year-old immunosuppressed man treated for re-
current lymphocytic leukemia and autoimmune hemolytic ane-
mia with chemotherapy and cyclosporin, presented with
papular and follicular skin eruptions and spiny keratosis in
May 2014 (Figure 1A). The lesions that had first been noticed
on his face in December 2013 gradually extended to the neck,
back, and extremities. Hair loss in his eyebrows and eyelashes
was also observed. Histopathological examination showed ker-
atotic masses expanding from the hair follicles, with widened
infundibuli and inner follicular layers containing viral inclu-
sions (Figure 1A). Plucked spicules and a skin biopsy were pos-
itive for TSPyV DNA (approximately 105 genome copies per
cell; Supplementary Table 1). After diagnosis of TS, topical an-
tiviral cidofovir cream treatment (1%) was administered twice a
Figure 1. Clinical, histopathological, and radiological characteristics of patients 1 and 2. A, Papules and spicules on the nose and left earlobe of patient 1 before (upper
images) and after (lower image) topical 1% cidofovir treatment. Vertical hematoxylin-eosin–stained section (×200) shows a distended hair follicle with disorganized inner root
sheath cells with eosinophilic trichohyalin granules and viral inclusions (lower left image). Magnetic resonance image with contrast enhancement of the brain shows one of the
cerebral lesions (arrow) observed in patient 1 (lower right image). B, Papules and spicules on the face of patient 2, accompanied by thickening of the skin and alopecia of the
eyelashes and eyebrows. Histopathological examination in patient 2 shows a dilated hair follicle with keratin plugging.
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day. Rapid improvement was seen in the patient’s face, which
was free of lesions within 4 weeks (Figure 1A, ear in lower
image) and showed a 104-fold reduction in TSPyV load (Sup-
plementary Table 1). After 14 weeks of treatment, his remaining
skin was also cleared and the treatment was ended. No nephro-
toxicity was observed.
By the end of 2014, when he was treated with steroids for re-
lapsing autoimmune hemolytic anemia, he briefly received ci-
dofovir intravenously (5 mg/kg, once per week) in an attempt
to reduce systemic viral replication (see below), but no signifi-
cant antiviral effect was observed. Along with the cutaneous
symptoms, in late 2013 the patient had also developed irrevers-
ible blindness and papilledema and lost pituitary function, and
small cerebral lesions were seen on a magnetic resonance image
(Figure 1A). Because these lesions proved not to be progressive,
cerebral localization of recurrent lymphocytic leukemia was
considered unlikely. Alternatively, the patient’s condition was
assumed to be infectious, possibly toxoplasmosis, and he was
treated accordingly. His lesions did not significantly improve
with treatment, consistent with negative CSF laboratory find-
ings for Toxoplasma gondii.
Patient 2, a 62-year-old woman who had received a kidney
transplant in 2009, presented early in 2011 with itchy, follicular,
hyperkeratotic skin lesions on her face and scattered over her
body (Figure 1B). She had first noticed the lesions a few
weeks earlier. Histopathological examination showed dilated
hair follicles with keratin plugging and sparse perifollicular
lymphocyte infiltration (Figure 1B). The initial differential diag-
nosis included a drug eruption, folliculitis, and atypical kerato-
sis pilaris. Tacrolimus, part of the patient’s immunosuppressive
regimen, was replaced by cyclosporine, and sequential topical
treatment with urea cream, adapalene gel and oral minocycline
was started, but this did not improve her condition. After histo-
pathological and clinical revision, TS was considered. A skin biop-
sy specimen was found to be positive for TSPyV DNA by PCR
(approximately 104 copies per cell; Supplementary Table 1), and
antiviral treatment was started with oral valgancyclovir, at a re-
duced dose of 450 mg once daily owing to impaired renal function.
The dosage of the immunosuppressant mycophenolate mofetil
was also reduced. After 5 months of treatment, the patient’s skin
lesions had improved markedly and her itch had resolved.
TSPyV Seroreactivity and Seroconversion
In serum and plasma samples obtained from both patients be-
fore, during, and after TS diagnosis, TSPyV-specific IgG seror-
esponses were detectable only after TS had erupted (Figure 2A;
Supplementary Table 1). IgG seroresponses against the related
Merkel cell polyomavirus and BKPyV were already detectable
before TS (Supplementary Table 1), demonstrating the ability
of these immunocompromised patients to raise comparable
seroresponses. In conjunction with the appearance of TSPyV-
specific IgG, a marked increase in TSPyV IgG avidity was
noted (Figure 2A). Moreover, TSPyV-specific IgM serores-
ponses were detected that preceded IgG seroconversion and
coincided with the first detection of TSPyV DNA in blood in
both patients (see below). In addition, in CSF from patient 1,
months after TS erupted, TSPyV-specific IgG seroconversion
was apparent (Supplementary Table 1).
TSPyV in Blood
Analysis of serum and plasma samples collected about the time
of TS diagnosis revealed the presence of high levels of TSPyV
DNA (approximately 108 copies/mL) in the blood of both pa-
tients just before onset of TS symptoms and before seroconver-
sion (Figure 2A). TSPyV DNAwas also found in other materials
(urine, feces, conjunctiva) (Supplementary Table 1). Because
some HPyVs are known to infect lymphocytes [9], we analyzed
fluorescence-activated cell sorted peripheral B-cell, T-cell, and
natural killer cell fractions in patient 1 for the presence of
TSPyV DNA. Mutually comparable low levels of TSPyV
DNA (<1 copy per cell) were detected, much lower than in
serum or plasma, suggesting that none of these cell types pref-
erentially harbored TSPyV (Supplementary Table 1).
TSPyV in CSF
Triggered by the high levels of viremia and the concomitant de-
velopment of blindness, pituitary failure, and cerebral lesions,
the involvement of the central nervous system in TSPyV infec-
tion was explored in patient 1. In 2 CSF samples from patient 1,
taken 1 year apart, a considerable amount of TSPyV DNA (105
copies/mL) was detected (Supplementary Table 1), while other
pathogens, including Toxoplasma gondii, Cryptococcus neofor-
mans, BKPyV, and JCPyV, were not found.
TSPyV Genome Rearrangements
To further explore these highly replicative, primary TSPyV in-
fections, we analyzed the NCCR of various TSPyV isolates from
both patients for the presence of specific genome rearrange-
ments reminiscent of reactivating, classic HPyV infection. Be-
sides a small number of 6 single-nucleotide polymorphisms,
all isolates obtained from skin, blood, urine, and CSF contained
genomes corresponding to the consensus TSPyV genome (Fig-
ure 2B) [10]. The typical NCCR duplications found in patho-
genic JCPyV and BKPyV isolates were not observed, but in
both urine and serum of each patient some isolates carried a
30–60-nucleotide NCCR deletion (Figure 2C–2D).
DISCUSSION
This detailed investigation of 2 TS cases revealed several previ-
ously unknown aspects of TSPyV infection, and of HPyV infec-
tions in general. The course, intensity, and maturation of the
measured TSPyV-specific IgG and IgM seroresponses point to
TSPyV primary infection as the cause of TS. Cross-recognition
of other HPyVs is unlikely because of the established high spe-
cificity of the serological methods used [6, 8]. The level of the
measured viral loads is also indicative of primary infection,
BRIEF REPORT • JID • 3
because high viral loads typically accompany primary infection.
Although the number of analyzed TS cases in this study is very
small, we assume that a primary TSPyV infection underlies
development of TS in general. This scenario provides an expla-
nation for the rarity of this disease, with primary TSPyV infec-
tion after childhood being rare and coincidence with severe
Figure 2. Detection of trichodysplasia spinulosa polyomavirus (TSPyV) DNA, TSPyV seroresponses, and TSPyV genome sequences. A, TSPyV DNA loads (bars) and serores-
ponses (lines) are shown for patients 1 (black) and 2 (red). TSPyV immunoglobulin (Ig) G seroresponses are shown in solid lines and closed symbols, IgM seroresponses in dashed
lines and open symbols. Time points on x-axis are relative to the first detection of TSPyV DNA in blood samples (viremia). Percentages next to closed IgG symbols represent IgG
avidity values. B, Linear representation of the circular, 5232 base pair–containing TSPyV genome with the position of each single-nucleotide polymorphism (SNP) compared with
the consensus TSPyV sequence [10], indicated by vertical lines for synonymous (gray) and nonsynonymous (red) substitutions). C, Sequence analysis of the noncoding control region
(NCCR) of TSPyV isolates from serum (red), skin (olive), urine (yellow), and CSF (white). Time points (t) refer to those on the x-axis in A. Vertical lines represent presence of SNP;
hatching, stretch of DNAwhere mixed sequences were found, indicative of a deletion in the area. Numbers refer to nucleotide positions within the NCCR. D, Graphic representation
of sequenced individually cloned polymerase chain reaction products spanning the NCCR of urine samples from both patients. Numbers refer to nucleotide positions within the
NCCR. Apart from full-length, consensus sequence-containing clones (clone 1 of patients 1 and 2) [10], specific deletions were observed between nucleotides 134–193 (clone 2),
135–165 (clone 3), and 143–173 (clone 4) for patient 1, and between nucleotides 134–193 (clone 2), 135–165 (clone 3), and 134–158 (clone 4) for patient 2.
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immunosuppression even rarer. Whether this pattern holds for
other rare HPyV-related diseases, for example those caused by
HPyV7 and NJPyV [11, 12], deserves further study.
The marked increase in TSPyV IgG seroreactivity after pri-
mary infection resembles that of BKPyV, another HPyV with
established viremic potential [6]. From findings in immuno-
competent children, it is known that low levels of viremia some-
times accompany asymptomatic primary TSPyV infection [8].
Preliminary analysis of a previously described cohort of asymp-
tomatic, mostly TSPyV-seropositive adult kidney transplant re-
cipients, showed the presence of low-level TSPyV viremia in
one-third of the subjects, a pattern recently observed by others
as well [13]. In all, it seems that TSPyV reactivation may be ac-
companied by low-level viremia, whereas manifest TS is accom-
panied by high level viremia resulting from disseminated
primary TSPyV infection in a naive immunocompromised host.
Because we hardly detected TSPyV DNA in peripheral lym-
phocyte populations, these cells do not seem to be potential
sites for (latent) TSPyV infection. The course of infection,
with viremia preceding development of cutaneous lesions, ar-
gues against the skin being the main porte d’entrée. Because
viral DNA has been detected in tonsils and nasopharyngeal
swabs [14], the nasopharynx might play an important role in
TSPyV infection.
To our knowledge TSPyV-DNA detection in CSF has not
been reported before. We considered the intrathecal presence
of large amounts of viral DNA and specific antibodies sugges-
tive of central nervous system involvement in TSPyV infection.
Whether the development of the neuroendocrinological signs
and cerebral lesions concurrent with TS in patient 1 were caus-
ally related to TSPyV infection could not be assessed. A cerebral
biopsy was considered too dangerous, and ocular fluid was not
available for analysis. It is interesting to note that other novel
HPyVs, HPyV6 and NJPyV, were recently found to be associat-
ed with (JCPyV-negative) encephalopathy [15] and blindness
[12], respectively.
Rearranged NCCRs, in particular those containing the typi-
cal duplications seen in JCPyV genomes isolated from CSF
samples in patients with PML [3], were not found for TSPyV.
However, in both patients, a number of TSPyV isolates from
serum and urine samples contained specific NCCR deletions.
Whether these findings speak against or in favor of reactivation
is unclear, especially because we are unaware of the nature,
archetype or rearranged, of the TSPyV genomes reported in
the literature [10] and GenBank, which are usually obtained
from skin. Because the observed NCCR-deletions might affect
transcription factor binding and promoter activity, consequenc-
es for viral transcription and replication are worth studying.
In summary, this report provides strong evidence that novel
polyomavirus-associated disease is caused by primary infection
later in life, in the course of immunosuppression. These find-
ings can explain the rarity of some HPyV-associated diseases
and challenge the dogma that HPyV-associated diseases are
caused by viral reactivation. Whether determination of HPyV
serostatus before immunosuppression could be useful to identi-
fy immunosuppressed patients at risk requires further study, as
does the potential contribution of TSPyV infection to disease of
the central nervous system.
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